Ophthalmic
Complex

NAD+ declines 40–50% between age 30 and 60. The retina, with one of the highest metabolic demands of any tissue, is especially vulnerable. NMN bypasses the rate-limiting NAMPT enzyme to restore NAD+ directly inside retinal cells, activating SIRT1 and SIRT3 neuroprotective pathways. The 500mg dose exceeds doses showing functional benefit in human RCTs and matches the molecule in the active NCT06991712 glaucoma trial.

Lutein concentrates in the macula to form macular pigment — the eye's natural blue-light filter. It absorbs high-energy blue light before it reaches the photoreceptors and directly quenches reactive oxygen species. The 10mg dose is the exact amount validated in the AREDS2 multi-centre RCT (n=4,203), reducing risk of advanced AMD progression by 18–26%.

Zeaxanthin concentrates at the foveal centre — the very centre of your vision — complementing lutein to provide full macular pigment coverage. Together, lutein and zeaxanthin at these exact doses are the most rigorously validated macular protection combination in ophthalmic history.

The 2025 Karolinska Institute study confirmed dysregulated one-carbon metabolism in human glaucoma tissue, and that B vitamin supplementation completely halted optic nerve axon degeneration without reducing eye pressure. Intessa uses the active forms — P5P and Methylcobalamin — bypassing the MTHFR conversion step that limits absorption in 40–60% of people.

Piperine is a bioavailability amplifier. It inhibits CYP3A4 and UDP-glucuronosyltransferase enzymes, and blocks P-glycoprotein efflux in the intestinal wall, increasing the absorption of all co-ingested nutrients by 30–60%. Every other ingredient in Intessa is delivered more effectively because piperine is present.